Abstract:Objective To understand the mechanism of the resistance of non‐small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) inhibitor treatment. Background NSCLC is one of the most common malignancies in the world, of which a group of patients have activating EGFR mutations. Icotinib and Gefitinib are two tyrosine kinase inhibitors (TKIs) that bind to the tyrosine kinase domain in EGFR and inhibit EGFR activity, which have been used to treat NSCLC. However, natural and acquired resistance significantly limits the efficacy of EGFR‐TKIs, and the mechanism of the resistance is not fully understood. Autophagy is a highly conserved, genetically programmed degradation pathway that removes damaged organelles and protein aggregates in response to various stimuli to maintain cellular homeostasis. Autophagy inhibits tumorigenesis but promotes tumor progression at later stages. Nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) is a transcription factor and regulates the expression of antioxidant genes. Activation of Nrf2 is a protective mechanism for normal cells under oxidative stress, and also for cancer cells from chemotherapeutic agents that facilitates cancer progression. Whether autophagy and Nrf2 activation contribute to the sensitivity of NSCLC to TKI treatment has been incompletely understood. Methods We compared the sensitivity of A549, an EGFR wild type cell line derived from lung carcinoma, and HCC827, an EGFR mutant cell line derived from lung adenocarcinoma, to TKI treatment, and determined the role of autophagy and Nrf2 activation in TKI‐mediated cell death. Results Icotinib and Gefitinib induced significant apoptosis in HCC827 cells in a dose‐dependent manner, while they did not cause apoptosis in A549 cells. TKI inhibitors induced autophagy flux and mTOR inhibition in HCC827 but not in A549 cells. Intriguingly, suppression of autophagy by chloroquine, a lysosomal inhibitor, did not affect TKI‐induced cell death. A549 cells had lower basal level of autophagy but higher basal level of Nrf2 activation than HCC827 cells. Brusatol, a Nrf2 inhibitor, did not affect autophagy in A549 or HCC827 cells, but significantly decreased the cell viability in A549 and HCC827 cells. However, Brusatol did not further sensitize A549 or HCC827 cells to TKI‐induced cell death. Conclusion A549 cells are more resistant to TKI‐induced apoptosis than HCC827 due to persistent activation of Nrf2. Although autophagy activity is higher in HCC827 cells than A549 cells, it is not essential for the sensitivity of HCC827 or A549 cells for TKI. Inhibition of Nrf2 reduces the cell viability of TKI resistant A549 cells although it does not show synergistic effects with TKI. Support or Funding Information NIH RO1 AA020518, NIH R01 DK 102142, P20 RR021940 (COBRE)

Nrf2 Promotes Progression of Non-Small Cell Lung Cancer Through Activating Autophagy

NUF2 Drives Cholangiocarcinoma Progression and Migration Via Inhibiting Autophagic Degradation of TFR1

“NRF2 Addiction” in Lung Cancer Cells and Its Impact on Cancer Therapy

Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer

Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers

Loss of Beclin1 expression and Nrf2 overexpression are associated with poor survival of patients with non-small cell lung cancer.

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer.

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis

Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer

Nrf2 but Not Autophagy Activation is Associated with Resistance to Egfr Inhibitor-Induced Lung Tumor Cell Apoptosis

Nuclear Factor Erythroid 2 (Nf-E2)-related Factor 2 (nrf2) in Autophagy-Induced Hepatocellular Carcinoma

Nrf2 promotes esophageal squamous cell carcinoma (ESCC) resistance to radiotherapy through the CaMKIIα-associated activation of autophagy

Targeting Nrf2/PHKG2 Axis to Enhance Radiosensitivity in NSCLC.

The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells Upon Stimulation of Reactive Oxygen Species.

Resveratrol, an activator of SIRT1, induces protective autophagy in non-small-cell lung cancer via inhibiting Akt/mTOR and activating p38-MAPK

Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks

Nrf2 in human cancers: biological significance and therapeutic potential

The Role of Expression of Nrf2 in Predicting Chemoresistance and Prognosis in Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based First-Line Chemotherapy

Autophagy Enhanced the Radioresistance of Non-Small Cell Lung Cancer by Regulating ROS Level under Hypoxia Condition